Procaps Group S.A.'s latest marketcap:
As of 07/05/2025, Procaps Group S.A.'s market capitalization has reached $157.95 M. According to our data, Procaps Group S.A. is the 21676th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 157.95 M |
| Revenue (ttm) | 414.1 M |
| Net Income (ttm) | 52.2 M |
| Shares Out | 112.82 M |
| EPS (ttm) | 0.52 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/29/2025 |
Procaps Group S.A.'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $157.95 M | -40.17% | 21676 |
| 12/31/2024 | $264.01 M | -42.51% | 45664 |
| 12/29/2023 | $459.19 M | -22.48% | 44019 |
| 12/30/2022 | $592.33 M | -46.15% | 42351 |
| 12/31/2021 | $1.1 B | 323.09% | 40473 |
| 12/31/2020 | $260 M | 8.29% | 37421 |
| 12/31/2019 | $240.09 M | 34870 |
Company Profile
About Procaps Group S.A.
Procaps Group S.A. is a global pharmaceutical company specializing in the development, production, and marketing of innovative healthcare solutions. Founded in 1977 and headquartered in Luxembourg, the company serves diverse therapeutic needs worldwide.
Key Offerings
- Branded Prescription Drugs: Covers therapeutic areas such as feminine care, pain relief, skin care, digestive health, cardiology, vision care, central nervous system, and respiratory health.
- Hospital-Use Pharmaceuticals: Includes antibiotics, blood clot treatments, immunosuppressants, oncology drugs, analgesics, and personal protective equipment.
- Over-the-Counter (OTC) Products: Features a broad portfolio across eight therapeutic categories, including gastrointestinal care, skin care, cough and cold relief, analgesics, urological health, and vitamins/minerals.
- Diabetes Solutions: Provides blood glucose meters, telemonitoring products, oral anti-diabetics, insulin delivery systems, and cosmeceuticals.
- Contract Manufacturing: Offers specialized drug development and soft gelatin capsule production services for third-party pharmaceutical companies.
Therapeutic Expertise
Procaps Group serves a wide range of medical needs, including antibiotics, anti-infectives, cardiovascular treatments, hormonal therapies, metabolic/endocrine support, nervous system care, ophthalmic solutions, osteoarticular treatments, and respiratory health products.
Frequently Asked Questions
-
What is Procaps Group S.A.'s (OTC-PROCF) current market cap?As of 07/05/2025, Procaps Group S.A. (including the parent company, if applicable) has an estimated market capitalization of $157.95 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Procaps Group S.A. (OTC-PROCF) rank globally by market cap?Procaps Group S.A. global market capitalization ranking is approximately 21676 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.